AVROBIO (AVRO)
(Delayed Data from NSDQ)
$1.21 USD
+0.03 (2.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
AVRO 1.21 +0.03(2.11%)
Will AVRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AVRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVRO
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
AVRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Other News for AVRO
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
AVROBIO’s Strategic Ambiguity: A Commitment to Analysis with Uncertain Outcomes for Shareholders
Avrobio (AVRO) Gets a Buy from Wells Fargo
Tectonic Therapeutic Announces Participation at Investor Conferences in March
Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion ...